AMP trims position in NKTR

Yesterday AMP trimmed its position in Nektar Therapeutics by trimming 33% of its position. Buoyed by recent positive Ph1/2 results for NKTR-214 in solid tumors in combination with Opdivo, AMP's position was up ~200% at the time of the sale.